Table 1.
Correlation between clinic and pathological features of patients with thyroid cancer and different tumor sub-types.
| Classic PTC | FV-PTC | TC-PTC | PD-PTC | FTC | p-value* | p-value** | p-value*** | |
|---|---|---|---|---|---|---|---|---|
| Gender | ||||||||
| Female | 14 (77.8) | 12 (80.0) | 7 (87.5) | 7 (100.0) | 6 (75.0) | 0.692 | 0.568 | 0.569 |
| Male | 4 (22.2) | 3 (20.0) | 1 (12.5) | 0 (0.0) | 2 (25.0) | |||
| Age, Mean ± SD | 33.7 ± 11.8 | 43.1 ± 17.3 | 51.4 ± 15.2 | 38.3 ± 19.7 | 58.5 ± 16.3 | 0.006 | 0.056 | 0.022 |
| Multifocality | ||||||||
| Unifocal | 9 (50.0) | 7 (46.7) | 4 (50.0) | 3 (42.9) | 5 (62.5) | 0.950 | 0.988 | 0.445 |
| Multifocal | 9 (50.0) | 8 (53.3) | 4 (50.0) | 4 (57.1) | 3 (37.5) | |||
| Concurrent CLT | ||||||||
| Absent | 13 (72.2) | 11 (73.3) | 6 (75.0) | 6 (85.7) | 6 (75.0) | 0.971 | 0.913 | 1.000 |
| Present | 5 (27.8) | 4 (26.7) | 2 (25.0) | 1 (14.3) | 2 (25.0) | |||
| pTNM | ||||||||
| I | 10 (55.6) | 9 (60.0) | 2 (25.0) | 6 (85.7) | 1 (12.5) | 0.035 | 0.025 | 0.073 |
| II | 4 (22.2) | 4 (26.7) | 1 (12.5) | 1 (14.3) | 3 (37.5) | |||
| III | 3 (16.7) | 2 (13.3) | 1 (12.5) | 0 (0.0) | 1 (12.5) | |||
| IV | 1 (5.6) | 0 (0.0) | 4 (50.0) | 0 (0.0) | 3 (37.5) | |||
| Lymph-node metastasis at diagnosis | ||||||||
| Absent | 7 (38.9) | 10 (66.7) | 3 (37.5) | 5 (71.4) | 8 (100.0) | 0.028 | 0.234 | 0.011 |
| Present | 11 (61.1) | 5 (33.3) | 5 (62.5) | 2 (28.6) | 0 (0.0) | |||
| Distant metastasis at diagnosis | ||||||||
| Absent | 16 (88.9) | 15 (100.0) | 6 (75.5) | 6 (87.5) | 5 (62.5) | 0.140 | 0.297 | 0.043 |
| Present | 2 (11.1) | 0 (0.0) | 2 (25.5) | 1 (14.3) | 3 (37.5) | |||
| Capsular invasion | ||||||||
| Absent | 17 (94.4) | 11 (73.3) | 7 (87.5) | 6 (85.7) | 4 (50.0) | 0.114 | 0.429 | 0.022 |
| Present | 1 (5.6) | 4 (26.7) | 1 (12.5) | 1 (14.3) | 4 (50.0) | |||
| Vascular invasion | ||||||||
| Absent | 15 (83.3) | 13 (86.7) | 5 (62.5) | 7 (100.0) | 3 (37.5) | 0.027 | 0.266 | 0.005 |
| Present | 3 (16.7) | 2 (13.3) | 3 (37.5) | 0 (0.0) | 5 (62.5) | |||
| Gross extrathyroid extension | ||||||||
| Absent | 14 (77.8) | 15 (100.0) | 1 (12.5) | 5 (71.4) | 7 (87.5) | <0.001 | <0.001 | 0.363 |
| Present | 4 (22.2) | 0 (0.0) | 7 (87.5) | 2 (28.6) | 1 (12.5) | |||
| Any invasion | ||||||||
| Absent | 12 (66.7) | 10 (66.7) | 1 (12.5) | 3 (42.9) | 0 (0.0) | 0.004 | 0.055 | 0.005 |
| Present | 6 (33.3) | 5 (33.3) | 7 (87.5) | 4 (57.1) | 8 (100.0) | |||
| RAI doses, Mean ± SD | 220.4 ± 173.8 | 268.0 ± 302.1 | 406.2 ± 322.3 | 142.8 ± 142.7 | 356.2 ± 323.4 | 0.201 | 0.123 | 0.548 |
Abbreviations: SD, standard deviation; CLT, chronic lymphocytic thyroiditis; PTC, papillary thyroid carcinoma; FV-PTC, follicular variant of PTC; TC-PTC, tall cell variant of PTC; PD-PTC, poorly differentiated, PTC; FTC, follicular thyroid carcinoma; RAI, radioactive iodine therapy cumulative doses.
Note: *comparison considering all different histologic subtypes (5 categories); **comparison considering different subtype of PTC (4 categories); ***comparison considering PTC versus FTC.